Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 3 diabetes

被引:166
作者
Bruno, G
Merletti, F
Biggeri, A
Bargero, G
Ferrero, S
Runzo, C
Cerai, SP
Pagano, G
Cavallo-Perin, P
机构
[1] Univ Turin, Dept Internal Med, I-10126 Turin, Italy
[2] Univ Turin, CERMS, Unit Canc Epidemiol, Turin, Italy
[3] Univ Turin, Ctr Oncol Prevent, Turin, Italy
[4] Univ Florence, Dept Stat G Parenti, Florence, Italy
[5] Santo Spirito Hosp, Alessandria, Italy
关键词
D O I
10.2337/diacare.27.11.2689
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE- The aim of this study was to assess in an 11-year survival follow-up of a population-based cohort of type 2 diabetes the predictive role of World Health Organization-defined metabolic syndrome, independent of conventional cardiovascular risk factors. RESEARCH DESIGN AND METHODS- During the follow-up (1991-2001), 1565 patients were regularly examined with centralized measurements of HbA(1c). The independent role of the metabolic syndrome as a predictor of all-cause and cardiovascular mortality was assessed with multivariate Cox proportional hazards modeling. RESULTS- At baseline, the prevalence of the metabolic syndrome was 75.6% (95% CI 73.6-77.9). Results are based on 685 deaths (520 with the metabolic syndrome and 165 without it) in 10,890.2 person-years of observations. With respect to subjects without the metabolic syndrome, those with the metabolic syndrome had a similar hazard ratio (HR) of cardiovascular mortality after adjustment for age, sex, smoking, total cholesterol level, and coronary heart disease. In contrast, relative to subjects with diabetes only, the HR of subjects with only one component of the syndrome was 2.92 (1.16-7.33), independent of other risk factors. CONCLUSIONS- we found that 1) the prevalence of the metabolic syndrome in a population-based cohort of type 2 diabetes is high (75.6%); 2) the metabolic syndrome is not a predictor of 11-year all-cause and cardiovascular mortality; and 3) more than twofold higher cardiovascular risk, independent of conventional risk factors, is evident in diabetic subjects with only one component of the syndrome compared with those with diabetes only. Categorizing type 2 diabetic subjects as having or not having the metabolic syndrome does not provide further prediction compared with the knowledge of its single components.
引用
收藏
页码:2689 / 2694
页数:6
相关论文
共 25 条
[1]   NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older [J].
Alexander, CM ;
Landsman, PB ;
Teutsch, SM ;
Haffner, SM .
DIABETES, 2003, 52 (05) :1210-1214
[2]  
[Anonymous], 1977, International Classification of Diseases
[3]  
[Anonymous], 2001, GUID DOC US IN VITR
[4]   The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study [J].
Bonora, E ;
Targher, G ;
Formentini, G ;
Calcaterra, F ;
Lombardi, S ;
Marini, F ;
Zenari, L ;
Saggiani, F ;
Poli, M ;
Perbellini, S ;
Raffaelli, A ;
Gemma, L ;
Santi, L ;
Bonadonna, RC ;
Muggeo, M .
DIABETIC MEDICINE, 2004, 21 (01) :52-58
[5]   Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus [J].
Bruno, G ;
CavalloPerin, P ;
Bargero, G ;
Borra, M ;
DErrico, N ;
Pagano, G .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (08) :653-657
[6]   Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus [J].
Bruno, G ;
Merletti, F ;
Boffetta, P ;
Cavallo-Perin, P ;
Bargero, G ;
Gallone, G ;
Pagano, G .
DIABETOLOGIA, 1999, 42 (03) :297-301
[7]   Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes [J].
Bruno, G ;
Biggeri, A ;
Merletti, F ;
Bargero, G ;
Ferrero, S ;
Pagano, G ;
Perin, PC .
DIABETES CARE, 2003, 26 (08) :2353-2358
[8]   Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects [J].
Bruno, G ;
CavalloPerin, P ;
Bargero, G ;
Borra, M ;
Calvi, V ;
DErrico, N ;
Deambrogio, P ;
Pagano, G .
DIABETES CARE, 1996, 19 (01) :43-47
[9]   A comparison of the prevalence of the metabolic syndrome using two proposed definitions [J].
Ford, ES ;
Giles, WH .
DIABETES CARE, 2003, 26 (03) :575-581
[10]   Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE [J].
Gerstein, HC .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 :S82-S85